Related Experiment Video
Updated: Jul 19, 2025
09:49
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
10.0K
Developments in 177Lu-based radiopharmaceutical therapy and dosimetry
Siju C George1,2, E James Jebaseelan Samuel2
1Radiation Oncology Department, Miami Cancer Institute, Baptist Health, Miami, FL, United States.
Frontiers in Chemistry
|August 16, 2023
Summary
Lutetium-177 (177Lu)-tagged radioligands offer targeted cancer therapy for conditions like neuroendocrine tumors and prostate cancer. This review examines current treatments, patient dosimetry, and future research directions for improved safety and efficacy.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiopharmaceutical Therapy
Background:
- Lutetium-177 (177Lu) is a key therapeutic radioisotope.
- 177Lu-tagged radioligands target specific cancer receptors.
- Applications include neuroendocrine tumors and metastatic prostate cancer.
Purpose of the Study:
- Review available 177Lu-labelled radioligands for patient treatment.
- Evaluate patient-specific dosimetry in clinical trials and literature.
- Discuss challenges and opportunities in dosimetry standards.
Main Methods:
- Literature review of clinical trials and scientific publications.
- Analysis of current 177Lu-tagged radioligand therapies.
- Assessment of dosimetry standards and their impact on treatment.
Main Results:
- Overview of currently used 177Lu-labelled radioligands.
- Evaluation of the status and development of patient-specific dosimetry.
- Identification of challenges and opportunities in dosimetry.
Conclusions:
- 177Lu-tagged radioligand therapy is a growing treatment modality.
- Patient-specific dosimetry is crucial for safety and efficacy.
- Further research is needed to optimize treatment outcomes.
Keywords:
177Luabsorbed dosecalculation methodsclinical trialscontemporary developmentsdose calculationsimagingpatient-specific dosimetry
